Do you even shroom, bro?
There is mounting evidence, from the most ivory of academic towers, that psychedelic drugs have therapeutic effects. But convincing buttoned-up biotech investors to take a risk on the idea can sometimes be difficult, according to Ronan Levy, co-founder of Field Trip Psychedelics. And the people willing to bet on companies that think of psilocybin as a medicine have something in common.
“They’ve had their own psychedelic experience, and it’s been profoundly positive and profoundly meaningful,” Levy said. And that cuts across demographic lines, uniting 60-something former pharma CEOs and millennial tech millionaires, he said.
That was the case for Christian Angermayer, an investor in the psychedelics startup Compass Pathways whose life changed after eating some magic mushrooms on a yacht. And it suggests that biotech’s more staid moneychangers are perhaps an ayahuasca weekend away from getting on board.
“They’ve had their own psychedelic experience, and it’s been profoundly positive and profoundly meaningful,” Levy said. And that cuts across demographic lines, uniting 60-something former pharma CEOs and millennial tech millionaires, he said.
That was the case for Christian Angermayer, an investor in the psychedelics startup Compass Pathways whose life changed after eating some magic mushrooms on a yacht. And it suggests that biotech’s more staid moneychangers are perhaps an ayahuasca weekend away from getting on board.
.png)
No hay comentarios:
Publicar un comentario